CD274 and cancer: As current standardized methods to using PD-L1 immunohistochemical expression continue to mature in a fit-for-purpose and cancer-specific manner, we are simultaneously witnessing the development of novel multiplexed approaches to interrogate the tumor and its microenvironment at a multi-dimensional scale to complement PD-L1 as a biomarker.